Wellmind Vertigo

Semecarpus Anacardium Juice, Anamirta Cocculus Seed, Conium Maculatum Flowering Top, Kerosene, And Selenium

Medinatura Inc.
Human Prescription Drug
NDC 50114-9001

Wellmind Vertigo also known as Semecarpus Anacardium Juice, Anamirta Cocculus Seed, Conium Maculatum Flowering Top, Kerosene, And Selenium is a human prescription drug labeled by 'Medinatura Inc.'. National Drug Code (NDC) number for Wellmind Vertigo is 50114-9001. This drug is available in dosage form of Tablet. The names of the active, medicinal ingredients in Wellmind Vertigo drug includes Anamirta Cocculus Seed - 4 [hp_X]/1 Conium Maculatum Flowering Top - 3 [hp_X]/1 Petroleum Alkylate - 8 [hp_X]/1 Selenium - 6 [hp_X]/1 Semecarpus Anacardium Juice - 6 [hp_X]/1 . The currest status of Wellmind Vertigo drug is Active.

Drug Information:

Drug NDC:	50114-9001
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name:	Wellmind Vertigo
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type:	Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name:	Semecarpus Anacardium Juice, Anamirta Cocculus Seed, Conium Maculatum Flowering Top, Kerosene, And Selenium
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name:	Medinatura Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form:	Tablet
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status:	Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:	ANAMIRTA COCCULUS SEED - 4 [hp_X]/1 CONIUM MACULATUM FLOWERING TOP - 3 [hp_X]/1 PETROLEUM ALKYLATE - 8 [hp_X]/1 SELENIUM - 6 [hp_X]/1 SEMECARPUS ANACARDIUM JUICE - 6 [hp_X]/1
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:	ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Marketing Category:	UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date:	01 Jan, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date:	31 Aug, 2024
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date:	14 Jun, 2026
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.

Manufacturer Name:	MediNatura Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:	Yes
Whether or not the drug has been repackaged for distribution.
UNII:	810258W28U Q28R5GF371 Y61895R84U H6241UJ22B Y0F0BU8RDU
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDC	Description	Marketing Start Date	Marketing End Date	Sample Available
50114-9001-2	1 BOTTLE in 1 CARTON (50114-9001-2) / 100 TABLET in 1 BOTTLE	01 Jan, 2015	31 Aug, 2024	No
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Other medicines with the same generic name

Wellmind Vertigo

Semecarpus Anacardium Juice & more..

Tablet
MediNatura Inc.
NDC: 50114-9001

Product Elements:

Wellmind vertigo semecarpus anacardium juice, anamirta cocculus seed, conium maculatum flowering top, kerosene, and selenium semecarpus anacardium juice semecarpus anacardium juice anamirta cocculus seed anamirta cocculus seed conium maculatum flowering top conium maculatum flowering top petroleum alkylate petroleum alkylate selenium selenium lactose magnesium stearate mountain

Indications and Usage:

Indications & usage wellmind tm vertigo tablets are a homeopathic drug product indicated for the treatment of vertigo/dizziness ofvarious origins; mild cognitive impairment (mci) such as lack of concentration and forgetfulness.

Warnings and Cautions:

Warnings none

Dosage and Administration:

Dosage and administration general considerations â¢ the dosage schedules listed below can be used as a general guide for the administration of wellmind tm vertigo tablets. â¢ allow tablets to dissolve completely in the mouth, do not swallow. standard dosage: adults and children 12 years and older: 3 tablets per day, taking 1 tablet every 4 to 6 hours. acute dosage:adults and children 12 years and older: 1 tablet every Â½ to 1 hour until symptoms lessen, then continue with standard dosage. do not exceed 12 tablets in 24 hours.

Dosage Forms and Strength:

Dosage & administration 300 mg tablets each containing the active ingredients in the strengths listed under description.

Contraindications:

Contraindications â¢ wellmind tm vertigo tablets are contraindicated in patients with known hypersensitivity to wellmind tm vertigo or any of its ingredients. â¢ do not use during pregnancy or breastfeeding.

Adverse Reactions:

Adverse reactions post-marketing experience â¢ no adverse events with a causal relationship to wellmind tm vertigo tablets have been reported.

Overdosage:

Overdosage no negative effects of an overdose have been reported and none are expected due to the homeopathic dilutions.

Description:

Description each 300 mg tablet contains: active ingredients: ingredient name potency quantity final dilution anacardium orientale 6x 10 mg 7.5x cocculus indicus 4x 210 mg 4.15x conium maculatum 3x 30 mg 4x petroleum 8x 20 mg 9.2x selenium metallicum 6x 10 mg 7.5x selenium metallicum 12x 10 mg 13.5x selenium metallicum 30x 10 mg 31.5x

Clinical Pharmacology:

Clinical pharmacology mechanism of action the exact mechanism of wellmind tm vertigo tablets is not fully understood. pharmacodynamics not applicable for homeopathic medicinal products.

Package Label Principal Display Panel:

Wellmind vertigo rx tablet.jpg

Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.